Rani Therapeutics Holdings Inc (RANI) — Tangible Net Worth Ratio
Rani Therapeutics Holdings Inc (RANI) has a Tangible Net Worth Ratio of 100.0% as of December 2024. This metric is calculated by deducting intangible assets ($0.00) from net assets ($3.49 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Rani Therapeutics Holdings Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Rani Therapeutics Holdings Inc Tangible Net Worth Ratio (2021–2024)
This chart shows how Rani Therapeutics Holdings Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 100.0%, reflecting net assets of $3.49 Million with intangible assets of $0.00 USD. See Rani Therapeutics Holdings Inc (RANI) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Rani Therapeutics Holdings Inc (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Rani Therapeutics Holdings Inc from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Rani Therapeutics Holdings Inc (RANI) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $3.49 Million | $0.00 | $36.63 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $25.44 Million | $0.00 | $57.92 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $74.00 Million | $0.00 | $108.03 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $121.57 Million | $0.00 | $124.21 Million | — |